Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci197192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Rongzhong Xu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine…. Hauptthemen laut MEDLINE: DNA Topoisomerases, Type II, Topoisomerase II Inhibitors, Proto-Oncogene Proteins p21(ras), Mutation. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.
- Predicine, Inc., Hayward, California, USA.
Zitieren
APA
Xu, R., Wang, D., Ma, G., Yuan, X., Chu, Q., Fan, S., Zhang, R., Du, P., Jia, S., Leal, T. A., Ramalingam, S. S., Chen, Z., & Sun, S. Y. (2026). Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models. Journal of Clinical Investigation. https://doi.org/10.1172/jci197192
Vancouver
Xu R, Wang D, Ma G, Yuan X, Chu Q, Fan S, et al. Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models. Journal of Clinical Investigation. 2026. doi:10.1172/jci197192
BibTeX
@article{Xu2026,
author = {Xu, Rongzhong and Wang, Dongsheng and Ma, Guangzhi and Yuan, Xun and Chu, Qian and Fan, Songqing and Zhang, Rener and Du, Pan and Jia, Shidong and Leal, Ticiana A and Ramalingam, Suresh S and Chen, Zhen and Sun, Shi-Yong},
title = {Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci197192}
}
EUVIMED